China Capital Markets Weekly: Chip Expansion and the Quality of Earnings

Weekly dashboard

Review activity at a glance

0
New acceptances: 10
Published responses: 2*
Committee passes: 1
Registration results

* One committee pass is verified in full; the second is cross-checked, with the original BSE result attachment unavailable. Responses count verified Shanghai and Shenzhen full texts only.

Executive summary

This week in focus

Huazhuo Jingke and Changjing Technology illustrate how loss-making status, asset values and business-model expansion shape disclosure questions. A September 18 whistleblower reward notice implements an existing framework; it is not a new rule or seventeen new penalties. Earlier private-fund and futures measures remain continuing matters.

Contents

Weekly overview

No newly accepted IPO application or newly published IPO review rule was confirmed for the week. Ten inquiry or implementation responses were verified against full-text files published by the Shanghai and Shenzhen stock exchanges: two on the STAR Market, four on the Shenzhen Main Board and four on ChiNext. Guangdong Biomed Technology passed the Shenzhen Stock Exchange listing committee review, while Youbang Technology received an IPO registration approval.

For the Beijing Stock Exchange, Yantai Jiumu Chemical’s listing committee approval and Jiangsu Suxun New Material’s submission for registration were cross-checked through company disclosures or reporting derived from exchange data. The BSE’s original project pages and attachments were not consistently accessible during this review, so these items are separately labelled and are not treated as equivalent to the full-text Shanghai and Shenzhen verification set.

Continuing measures do not become new rules

No additional legal or regulatory text first published during September 14–20 was confirmed in the supplementary official-channel review. The September 4 private-fund consultation remains open until October 4. The September 11 futures measures take effect January 1, 2027; neither is counted again as new rulemaking this week.

The CSRC’s September 18 whistleblower reward notice implements an existing framework. It is not a new reward rule or seventeen new penalties. Registration runs until December 18, with identity and evidentiary requirements. An external allegation must still be distinguished from an authority’s established findings.

Review Activity by Board

Board	New Inquiry Letters	Full-Text Responses Verified	Committee / Passed	Submitted for Registration	Registration Result
Shanghai Main Board	0	0	0 / 0	0	0
STAR Market	0	2	0 / 0	0	0
Shenzhen Main Board	0	4	0 / 0	0	0
ChiNext	0	4	1 / 1	0	1
Beijing Stock Exchange	Pending verification	Original files pending	1 / 1*	1*	0

The asterisk indicates that the procedural status was cross-checked through a company disclosure or a source derived from exchange data, while the original BSE attachment remained unavailable. A project status shown as “under inquiry” does not by itself establish whether a new inquiry letter, a response or only updated filing material was published during the week.

What the Full-Text Responses Show

The ten verified response files show that exchange review continues to connect business claims with accounting evidence and legal ownership. Beijing Huazhuo Jingke’s first-round response covers product competitiveness, core technology, continued losses, revenue recognition, customers, procurement, gross margin, receivables, inventory, long-term assets, share-based payments, disclosure and accounting error corrections. Jiangsu Changjing Technology’s response links its transition to a “Fabless plus IDM” model with historical shareholding matters, related-party issues, customer and supplier evidence, gross margin, receivables, inventory, goodwill and other financial items.

For Huazhuo Jingke, readers can test the growth story against continued losses, collections, and the assets needed to deliver products. Changjing’s operating-model change raises a related question: how do existing facilities, acquired assets, and planned capacity fit the sales forecast? The exchange’s questions identify what needs explaining; they are not findings of misconduct.

Chip expansion: one operating model, three evidence tests. Changjing inquiry response, 18 September 2026; schematic review questions. — **Chip expansion: one operating model, three evidence tests**Source: Changjing inquiry response, 18 September 2026; schematic review questions.

Procedural Accuracy Matters

Listing committee approval, submission for registration, registration approval and actual listing are separate stages. Guangdong Biomed Technology’s committee approval does not mean that registration or listing has been completed. Youbang Technology’s registration approval is a later procedural step, but it still does not remove the need to monitor subsequent material events and disclosure updates.

Regulatory and Enforcement Developments

On September 18, the China Securities Regulatory Commission announced its intention to reward whistleblowers connected with 17 identified enforcement matters and opened a registration period running through December 18, 2026. This is an enforcement and reporting-mechanism development, not an IPO review rule.

Selected official regional indexes for Xinjiang, Zhejiang, Hunan and Shenzhen showed 20 administrative regulatory measure decisions published during the week. That is a sample count, not a nationwide total. The reviewed Shenzhen measures included a warning letter concerning an independent director’s annual reporting duty and measures against an investment consulting firm involving internal controls, marketing, personnel qualifications, investor suitability and compliance management. Administrative regulatory measures should not be described as administrative penalties unless the issuing authority has made that classification.

Evidence Gaps

The BSE website produced redirect or access restrictions during this review. Original project pages, inquiry-response attachments and meeting-result files could not be downloaded consistently. Regional CSRC offices also do not provide one stable nationwide weekly index. This article distinguishes primary official evidence, official index evidence, secondary exchange-data reporting and unresolved leads. Items without sufficient primary evidence are not used to support definitive conclusions.

What readers can check

When a response adds a material fact, compare it with the latest prospectus and financial statements. A change in customer demand, product mix, or capacity plans should be reflected consistently in forecasts and asset assumptions. Claims such as “first” or “leading” are more useful when the filing defines the comparison group and provides a source readers can check.

Public Sources

At the October 3, 2026 accessibility check, some BSE project and disclosure links returned redirect or access restrictions. Historical official URLs are retained for source identification, but their current accessibility could not be confirmed. The access limitation is not evidence that the underlying documents or review events did not exist.

Disclaimer

This article is based solely on publicly available information identified by the stated research cut-off, with regulatory legal materials supplemented and checked on October 3, 2026. It is provided for general information and research purposes only and does not constitute investment, legal or accounting advice, or a factual finding concerning any issuer, intermediary or other person. Public records may later be updated, supplemented or corrected. Readers should consult the latest official filings and decisions.